OCT 30, 2019 1:06 PM PDT

Investigating a common therapeutic in ADHD treatment

WRITTEN BY: Nouran Amin

Attention-Deficit Hyperactivity Disorder (ADHD) is a widespread condition with variable underlying causes. A common therapeutic, called methylphenidate, seeks to treat symptoms of ADHD by moderating the brain's dopamine level which is a neurotransmitter involved reward systems. But, the exact mechanism to how methylphenidate works remains largely understood.

Learn more about ADHD:

"We know quite a bit about how methylphenidate works at the molecular level, but not how it affects greater neural systems. It's still a mystery how this drug improves symptoms of ADHD," said Professor Jeff Wickens of Okinawa Institute of Science and Technology Graduate University (OIST)'s Neurobiology Research Unit. "This mystery leads us to explore how different parts of the brain interact to produce therapeutic effects."

To examine its therapeutic effects, researchers investigated the action of the drug in rat models. Researchers used dopamine cell recordings, electrochemical monitoring and computer modeling to bring renewed knowledge on methylphenidate's therapeutic actions in ADHD.

"When you use methylphenidate in the intact brain there's a neural regulation mechanism to compensate for the direct effects of the drug," said Wickens. "Methylphenidate's therapeutic effects could be indirect consequences of this feedback loop."

Findings were published in Progress in Neurobiology and describes how researcher’s administered a concentration of 5.0 mg/kg to a group of adult male rats while the control received no drugs. Researchers first believed that methylphenidate blocks the reuptake of dopamine by receptors in the brain and that should increase the phasic dopamine signal. However, what happened instead was the opposite--methylphenidate decreased the phasic dopamine signal.

Professor Jeff Wickens and technician Kavinda Liyanagama study data from experiments looking at dopamine release in rat brains. Credit: OIST.edu

Computer analysis suggests that methylphenidate mainly affects the tonic dopamine signal and shifts in such signal may improve ADHD symptoms. Researchers are now hopeful to continue their studies in animal models of ADHD and examine feedback loops under such conditions.

Source: Science Daily

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 21, 2022
Cannabis Sciences
One of the most lucrative skillsets in cannabis
APR 21, 2022
One of the most lucrative skillsets in cannabis
For anyone looking for a well-compensated, in demand job in the cannabis industry, you can't go wrong with becoming an e ...
MAY 02, 2022
Drug Discovery & Development
Synthetic Coating Improves Survival of Oral Medications During Digestion
MAY 02, 2022
Synthetic Coating Improves Survival of Oral Medications During Digestion
We’re probably all familiar with the (sometimes unpleasant) experience of swallowing pills. Whether ibuprofen for ...
MAY 19, 2022
Drug Discovery & Development
Experimental Drug Shows Promise Against ALS
MAY 19, 2022
Experimental Drug Shows Promise Against ALS
A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corres ...
MAY 20, 2022
Drug Discovery & Development
Drug Shows Promise in treating Spinal Cord Injury
MAY 20, 2022
Drug Shows Promise in treating Spinal Cord Injury
A drug developed by AstraZeneca preserves 80% of nerve function following spinal cord compression injury. The correspond ...
MAY 25, 2022
Neuroscience
Exploring Drug Targets in Neurodegenerative Diseases
MAY 25, 2022
Exploring Drug Targets in Neurodegenerative Diseases
Introduction Life expectancy has increased globally over the last several decades. However, longer life expectancy comes ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
Loading Comments...